BBM H803
Alternative Names: BBM-H803Latest Information Update: 12 Jan 2024
At a glance
- Originator Belief Biomed
- Class Antihaemorrhagics; Gene therapies
- Mechanism of Action Factor VIII replacements; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Haemophilia A
Most Recent Events
- 31 Oct 2023 Phase-I/II clinical trials in Haemophilia A in China (IV) (NCT06111638)
- 31 Jul 2023 National Medical Products Administration (NMPA) approves IND application for BBM H803 in Haemophilia A
- 31 May 2023 Belief Biomed files an IND application with the National Medical Products Administration (NMPA) in China for Haemophilia A